CTOs on the Move

Verinetics

www.verinetics.com

 
Verinetics is a company that provides the DispenSecur solution for Opioid Medication Management, which offers better control for controlled substances and integrates into existing pharmacy and patient management practices.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Biopure Corporation

Biopure Corporation is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BC Technical

BC Technical’s leadership team has over 100 years of combined experience in the medical imaging services market.

Akorn

At Akorn, we develop, manufacture and market specialty pharmaceuticals, including prescription, consumer health and animal health products. As an industry leader in branded and generic products in alternate dosage forms such as ophthalmics, injectables, oral liquids, otics, topicals, inhalants and nasal sprays, we focus each day on our mission to improve lives, through the quality, availability and affordability of our products. Akorn has Research and Development facilities in Vernon Hills, IL and Cranbury, NJ that provide a robust and continuous pipeline of new products. Akorn`s manufacturing facilities are located in Decatur, IL; Somerset, NJ; Amityville, NY and Hettlingen, Switzerland. In anticipation of long-term, substantial growth, we offer challenging, attractive career opportunities along with competitive salaries and comprehensive benefits. Akorn is an Equal Opportunity Employer. M/F/V/D.

Vapotherm

Vapotherm Inc., is a publicly held corporation based in Exeter, New Hampshire that was founded in 1999 as a medical device manufacturer after creating the first heated and humidified high flow therapy nasal cannula system.

Context Therapeutics

Context Therapeutics Inc. (Nasdaq: CNTX) is a women`s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The Company`s robust clinical program for lead candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. ONA-XR is a novel small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women`s cancers.